- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941180
BTK Inhibitor-Containing Bridging Therapy and CAR-T Outcomes in R/R LBCL
Association of Disease Control After BTK Inhibitor-Containing Bridging Therapy and Systemic Inflammatory Phenotypes With CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma
This observational study will examine outcomes of CAR-T cell therapy in adults with large B-cell lymphoma that has returned or has not responded to prior treatment. Participants will already have received bridging therapy that includes a BTK inhibitor before CAR-T cell infusion.
Researchers will compare outcomes between participants whose lymphoma responded to bridging therapy before CAR-T cell infusion and those whose lymphoma did not respond. The study will use medical records, imaging results, laboratory tests, treatment information, and follow-up data collected during usual care. It will not assign treatment, change medical care, or require extra tests or blood samples.
The study will assess lymphoma response after CAR-T cell therapy, safety, survival, and changes in routine blood markers of inflammation after CAR-T cell therapy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population comprises adults with relapsed or refractory large B-cell lymphoma (LBCL) who receive routine CAR-T cell therapy at a single center in China. Eligible patients receive BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy and have evaluable disease status after bridging therapy and before CAR-T cell infusion. Patients treated before ethics approval will be identified retrospectively from the center's CAR-T treatment records and routine medical records; eligible patients treated after ethics approval will be enrolled prospectively using the same criteria.
Description
Inclusion Criteria:
- Age ≥18 year.
- Relapsed or refractory large B-cell lymphoma (LBCL) after one or more prior lines of systemic therapy, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); diffuse large B-cell lymphoma transformed from follicular lymphoma (tFL); grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL); and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit lymphoma, DHL/THL).
- Completion of CAR-T cell infusion at this center.
- Receipt of BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy.
- Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
- Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
Exclusion Criteria:
- Inability to verify the specific BTK inhibitor(s) used, treatment start and stop dates, or information on combination therapy, thereby precluding confirmation of exposure to BTK inhibitorcontaining bridging therapy.
- Absence of disease assessment data between bridging therapy and CAR-T cell infusion, with post-bridging disease status not determinable from imaging reports or medical records.
- Major discrepancies in key baseline or treatment data that persist after review of medical records, imaging, and treatment documentation, precluding determination of bridging exposure or group assignment.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: OTHER
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Bridging Response (CR/PR)
Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort achieved complete response (CR) or partial response (PR). Treatments were determined as part of usual clinical care and were not assigned by the study. |
Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study. CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study. |
|
No Bridging Response (SD/PD)
Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort had stable disease (SD) or progressive disease (PD). Treatments were determined as part of usual clinical care and were not assigned by the study. |
Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study. CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Best objective response rate after CAR-T cell infusion
Time Frame: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
The proportion of participants who achieve complete response (CR) or partial response (PR) at any time after CAR-T infusion and before first progression, death, initiation of new anti-lymphoma therapy, or last evaluable disease assessment. Participants without CR/PR before these events are classified as nonresponders; progression or death after CR/PR does not change responder status. |
At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of response
Time Frame: From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
|
Among participants who achieve CR or PR, duration of response is measured from the date of first documented CR or PR to disease progression or death from any cause, whichever occurs first. Participants without progression or death will be censored at the last evaluable disease assessment or before initiation of subsequent anti-lymphoma therapy. |
From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
|
|
Complete response rate at 1 month after CAR-T cell infusion
Time Frame: Approximately 1 month after CAR-T cell infusion.
|
Approximately 1 month after CAR-T cell infusion.
|
|
|
Best complete response rate after CAR-T cell infusion
Time Frame: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
|
|
Number of participants with CAR-T treatment-emergent adverse events
Time Frame: From CAR-T cell infusion to last follow-up.
|
The number and percentage of participants with any adverse event occurring after CAR-T cell infusion will be reported. Safety events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, prolonged cytopenia, death, and other clinically documented adverse events considered related to CAR-T cell therapy. CRS and ICANS will be graded according to ASTCT consensus criteria; other events will be collected from routine clinical, laboratory, and medical-record data. |
From CAR-T cell infusion to last follow-up.
|
|
Objective response rate at 1 month after CAR-T cell infusion
Time Frame: Approximately 1 month after CAR-T cell infusion.
|
Approximately 1 month after CAR-T cell infusion.
|
|
|
Objective response rate at 3 month after CAR-T cell infusion
Time Frame: Approximately 3 months after CAR-T cell infusion.
|
Approximately 3 months after CAR-T cell infusion.
|
|
|
Complete response rate at 3 months after CAR-T cell infusion
Time Frame: 3 months after CAR-T cell infusion
|
3 months after CAR-T cell infusion
|
|
|
Progression-free survival
Time Frame: From CAR-T infusion to first progression, death, or last follow-up.
|
From CAR-T infusion to first progression, death, or last follow-up.
|
|
|
Overall survival
Time Frame: From CAR-T infusion to death from any cause or last follow-up.
|
From CAR-T infusion to death from any cause or last follow-up.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTK-CART-2026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.